CONTACT US

Products

Encouraging research and development of new products through employee initiatives and strategic alliances is key to serving and anticipating the changing needs of customers and patients.

About Lipofen® (fenofibrate capsules USP)

Lipofen® (fenofibrate capsules USP)

To report SUSPECTED ADVERSE REACTIONS, contact Kowa Pharmaceuticals America, Inc. at 1 (877) 334-3464 or FDA at 1 (800) 332-1088 or via the web at www.fda.gov/medwatch/index.html for voluntary reporting of adverse reactions.

For additional information, please see the Full Lipofen® Prescribing Information.

About LIVALO® (pitavastatin) tablets

New products through research and development

LIVALO is an HMG-CoA (3-hydroxy-3-methyl-glutaryl-co-enzyme A) reductase inhibitor (statin) developed in Japan and indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B) and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia. LIVALO is only minimally metabolized by the liver’s cytochrome P450 enzyme system, which may help reduce its potential for drug-drug interactions mediated by this system.

The efficacy of LIVALO has been evaluated against atorvastatin, simvastatin and pravastatin in patients with primary hyperlipidemia or mixed dyslipidemia. Since its launch in Japan (2003), South Korea (2005), Thailand (2008), China (2009) and the United States (2010), LIVALO has been successfully used to manage cholesterol levels for a range of patients, including the elderly, patients with diabetes and those whose treatment is complicated by concurrent disease and multiple drug regimens.

For additional information on LIVALO, see below:

Important Safety Information for LIVALO® (pitavastatin) tablets

Who should NOT take LIVALO? LIVALO is not right for everyone. Do not take LIVALO if:

What is the most important information I should know and talk to my doctor about?

What are the most common side effects of LIVALO?
The most common side effects of LIVALO in clinical studies were:

This is not a complete list of side effects. Talk to your healthcare provider for more information.
You are encouraged to report negative side effects of all drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

How should I store and take LIVALO?

Other important information I should know about LIVALO.

For additional information, please see the full Prescribing Information.

LIVALO is a registered trademark of the Kowa group of companies.
© Kowa Pharmaceuticals America, Inc. (2016)
All rights reserved. LIV-MT-2371LIV-MT-2372 November 2016.

All other trademarks are the properties of their respective owners.
This site is intended for US Residents ages 18 and over.

Development Programs: Our Pipeline of Products

Kowa’s Research & Development activities are carried out at the company’s laboratories in Tokyo and Fuji. The focus is on lifestyle-related diseases, immune disorders and allergy, and dermatology and ophthalmology.

Kowa Research Institute is responsible for the United States development of Kowa’s new drug candidates. Kowa currently has several drugs currently in Phase I or later clinical development, for conditions such as dyslipidemia, type 2 diabetes mellitus and cancer. Please click here for an overview of Kowa’s drug candidates currently in Phase I or later clinical development.

Kowa Company, Ltd.

Established in 1894, KCL is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products.

For more information, please visit the KCL products website.